1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Harbin Gloria Pharmaceuticals Co., Ltd. Class A

Harbin Gloria Pharmaceuticals Co., Ltd. Class A

SSZSE:002437
3.08
CNY
+0.04
(+1.32%)
0.17EPS
16.20P/E
6.02BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.62
2.72
1.25
1.37
1.38
2.49
2.3
1.39
1.43
1.41
1.19
1.11
0.97
0.92
Basic EPS, GAAP
0.11
0.63
0.31
0.33
0.14
0.06
-1.21
0.18
0.02
-0.13
0.05
0.11
0.17
0.17
Free Cash Flow per Basic Share
0.14
0.78
0.2
0.39
0.21
0.48
0.26
-0.01
0.11
0.1
0.11
0.16
0.11
- -
Dividend per Share
0.08
0.08
0.07
0.12
0.12
0.08
0.08
0.06
0.03
0.03
0.02
- -
- -
- -
Book Value per Share
1.14
1.38
1.55
1.8
1.9
1.99
0.69
0.84
0.86
0.74
0.76
0.86
1.03
1.11
Tangible Book Value per Share
0.76
0.35
-0.32
-0.08
-0.08
0.18
0.31
0.49
0.54
0.47
0.5
0.61
0.79
0.87
Basic Weighted Avg Shares
2,126
700
2,145
2,179
2,198
2,197
2,198
2,198
2,197
2,199
2,200
2,198
2,193
2,198
Sales/Revenue/Turnover
1,308
1,906
2,681
2,984
3,042
5,481
5,054
3,055
3,145
3,108
2,626
2,441
2,135
2,026
Operating Margin (%)
13.83
26.64
32.09
31.18
18.31
11.58
8.79
-0.57
5.58
4.38
9.37
11.99
12.59
14.35
Depreciation Expense
62
92
144
155
176
184
181
149
144
130
104
92
91
- -
Net Income, GAAP
227
444
665
717
310
126
-2,662
400
45
-291
120
233
377
366
Effective Tax Rate (%)
14.8
16.79
15.11
15.13
17.76
28.04
- -
27.68
37.38
- -
27.2
14.51
6.65
8.49
Profit Margin (%)
17.34
23.28
24.79
24.02
10.18
2.3
-52.67
13.1
1.43
-9.37
4.58
9.54
17.65
18.08
Working Capital
1,036
95
-1,939
-1,508
-1,244
-1,202
-1,563
-761
-478
-520
-257
54
521
659
LT Debt
- -
337
300
973
1,455
997
1
11
- -
- -
- -
2
1
- -
Total Equity
2,478
3,102
3,473
4,047
4,253
4,448
1,588
1,933
1,979
1,704
1,710
1,973
2,310
2,490
Return on Invested Capital (%)
6.97
11.72
11.13
8.75
3.57
1.58
- -
10.94
1.75
- -
4.53
10.99
17.07
15.93
Return on Capital (%)
8.57
13.24
12.25
10.73
5.79
3.06
- -
12.04
2.37
- -
5.16
10.61
17.08
15.82
Return on Common Equity (%)
9.6
16.4
20.7
19.46
7.61
2.94
-90.23
23.76
2.41
-16.53
7.31
12.89
17.76
16.63

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
91
21
89
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,232
2,230
2,230
Market Capitalization
6,852
7,760
6,021

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,319
1,349
1,405
Cash, Cash Equivalents & STI
930
948
1,025
Accounts Receivable, Net
127
135
120
Inventories
206
207
191
Total Current Liabilities
798
710
746
Payables & Accruals
- -
- -
- -
ST Debt
91
21
89
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.49%
4.26%
17.07%
Free Cash Flow
-82.26%
-171.85%
-28.3%
Net Income, GAAP
-325.92%
-164.3%
61.93%
Sales/Revenue/Turnover
1.28%
-6.66%
-12.51%
Total Cash Common Dividend
-24.29%
-50.46%
-87.08%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
593
628
636
583
2,441
2025
551
548
- -
470
2,135
2026
539
468
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.03
0.03
0.02
0.11
2025
0.03
0.03
- -
0.06
0.17
2026
0.04
0.03
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Lei Feng Guo
Full Time Employees
2,350
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 29, Beijing Road Beijing China 150025
IPO Date
Jun 7, 2010
Website
gloria.cc
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Harbin Gloria Pharmaceuticals Co., Ltd. (002437.SZ) engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. Founded in 2000 and headquartered in Harbin, the company operates in the generic and specialty pharmaceuticals sector, with a diversified portfolio spanning multiple therapeutic areas including cardiac cerebrovascular medications such as sodium creatine phosphate for injection and amlodipine olmesartan ester tablets; skeletal muscle system drugs like cervus and cucumis polypeptide injection; vitamins and minerals including multivitamin injections and compound vitamin injections; urinary system medications; antitumor drugs such as fluorouracil for injection, cyclophosphamide for injection, and pingyangmycin hydrochloride for injection; endocrine medicines like sitagliptin metformin sustained-release tablets; anti-infective drugs including compound cefaclor capsules; respiratory medications; antihistamines; peptic ulcer treatments; and other products encompassing orthopedic medicines, rheumatology drugs, digestive system medicines, liver disease medications, gynecology medications, circulatory system drugs, pediatrics, uropoiesis and reproduction therapies, and immune regulation products. The company maintains production facilities certified by international standards and serves healthcare providers across China, with overseas sales contributing a minor portion of revenue. Recent developments include the completion of an acquisition of an additional 10% stake in subsidiary Harbin Dandelion Pharmaceuticals Co., Ltd. from Harbin Hanjun; a CNY 100 million funding commitment to Guangzhou Gloria Biosciences Co., Ltd.; a planned CNY 200 million (approximately $27.5 million) acquisition of a 70% stake in Sheyang Zhenyang Hospital, marking entry into healthcare services; securing marketing rights for Eisai's mecobalamin injection; and a co-promotion agreement for a lipid-lowering drug. In 2024, the company reported chemical medicine sales of CNY 2.25 billion and traditional Chinese medicine sales of CNY 182 million, reflecting strategic expansion through epitaxial mergers, cooperative agents, independent R&D, and overseas introductions, alongside a pipeline of over 15 pharmaceutical candidates in clinical trials and oncology segment growth of 15% year-over-year.